Bosentan for the treatment of human immunodeficiency virus-associated pulmonary arterial hypertension

American Journal of Respiratory and Critical Care Medicine

Volumn 170, Issue 11, 2004, Pages 1212-1217

  Sitbon, Olivier ^a   Gressin, Virginie ^b   Speich, Rudolf ^b   Macdonald, Peter S ^b   Opravil, Milos ^b   Cooper, David A ^b   Fourme, Thierry ^b   Humbert, Marc ^b   Delfraissy, Jean François ^b   Simonneau, Gérald ^b  

^a HÔPITAL ANTOINE BÉCLÈRE   (France)

^b NONE

Author keywords

Bosentan; Doppler echocardiography; HIV infection; Pulmonary arterial hypertension; Quality of life

Indexed keywords

BOSENTAN;

ADULT; ARTICLE; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DOPPLER ECHOCARDIOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EXERCISE; FEMALE; FLUID RETENTION; HEADACHE; HEART INDEX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER DYSFUNCTION; MALE; MUSCLE CRAMP; PERIPHERAL EDEMA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; QUALITY OF LIFE; RISK ASSESSMENT; SIDE EFFECT; VOMITING;

ADULT; ANTIHYPERTENSIVE AGENTS; FEMALE; HIV INFECTIONS; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PULMONARY ARTERY; RECEPTORS, ENDOTHELIN; SULFONAMIDES; TREATMENT OUTCOME;

EID: 9644302310     PISSN: 1073449X     EISSN: None     Source Type: Journal    
DOI: 10.1164/rccm.200404-445OC     Document Type: Article

References (33)

1. Humbert M, Nunes H, Sitbon O, Parent F, Herve P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001;22:459-475.
2. Opravil M, Pechere M, Speich R, Joller-Jemelka HI, Jenni R, Russi EW, Hirschel B, Luthy R. HIV-associated primary pulmonary hypertension: a case control study. Swiss HIV Cohort Study. Am J Respir Crit Care Med 1997;155:990-995.
3. Speich R, Jenni R, Opravil M, Pfab M, Russi EW. Primary pulmonary hypertension in HIV infection. Chest 1991;100:1268-1271.
4. Mehta NJ, Khan IA, Mehta RN, Sepkowitz DA. HIV-Related pulmonary hypertension: analytic review of 131 cases. Chest 2000;118:1133-1141.
5. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA, Le Gall C, Parent F, Garcia G, Herve P, et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003;167:1433-1439.
6. Pellicelli AM, Barbaro G, Palmieri F, Girardi E, D'Ambrosio C, Rianda A, Barbarini G, Frigiotti D, Borgia MC, Petrosillo N, Primary pulmonary hypertension in HIV patients: a systematic review. Angiology 2001;52:31-41.
7. Petitpretz P, Brenot F, Azarian R, Parent F, Rain B, Herve P, Simonneau G. Pulmonary hypertension in patients with human immunodeficiency virus infection: comparison with primary pulmonary hypertension. Circulation 1994;89:2722-2727.
8. Ehrenreich H, Rieckmann P, Sinowatz F, Weih KA, Arthur LO, Goebel FD, Burd PR, Coligan JE, Clouse KA. Potent stimulation of monocytic endothelin-1 production by HIV-1 glycoprotein 120. J Immunol 1993;150:4601-4609.
9. Rolinski B, Geier SA, Sadri I, Klauss V, Bogner JR, Ehrenreich H, Goebel FD. Endothelin-1 immunoreactivity in plasma is elevated in HIV-1 infected patients with retinal microangiopathic syndrome. Clin Investis 1994;72:288-293.
10. Rolinski B, Heigermoser A, Lederer E, Bogner JR, Loch O, Goebel FD. Endothelin-1 is elevated in the cerebrospinal fluid of HIV-infected patients with encephalopathy. Infection 1999;27:244-247.
11. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF, Badesch DB, Roux S, Rainisio M, Bodin F, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358:1119-1123.
12. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A, Pulido T, Frost A, Roux S, Leconte I, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903.
13. Sitbon O, Gressin V, Speich R, Opravil M, Macdonald PS, Cooper DA, Fourme T, Simonneau G. Hemodynamic and clinical improvement with bosentan in patients with pulmonary arterial hypertension associated with HIV infection [abstract]. Eur Heart J 2003;24:482.
14. Sitbon O, Gressin V, Speich R, Opravil M, Macdonald PS, Cooper DA, Rainisio M. Bosentan in pulmonary arterial hypertension associated with HIV infection [abstract]. Eur Respir J 2003;22:563S.
15. Opravil M, Sitbon O, Gressin V, Speich R, Macdonald PS, Cooper DA, Rainisio M, Delfraissy J-F, Simonneau G. Safety and efficacy of bosentan in pulmonary arterial hypertension associated with HIV infection [abstract]. Antivir Ther 2003;8:S469.
16. Cooper DA, Macdonald PS, Sitbon O, Delfraissy J-F, Gressin V, Speich R, Opravil M, Simonneau G. Bosentan treatment in patients with pulmonary arterial hypertension associated with HIV infection [abstract]. Australasian Soc HIV Med 2003; p. 100.
17. Guyatt GH, Sullivan MJ, Thompson PJ, Fallen EL, Pugsley SO, Taylor DW, Berman LB. The 6-minute walk: a new measure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132:919-923.
18. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves BM, Tapson VF, Bourge RC, Brundage BH, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334:296-302.
19. ATS statement, guidelines for the six-minute walk test. Am J Respir Crit Care Med 2002;166:111-117.
20. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T, Espinola-Zavaleta N, Rocchi G, Manes A, Frantz R, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographicand doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003;41:1380-1386.
21. Wu AW, Hays RD, Kelly S, Malitz F, Bozzette SA. Applications of the Medical Outcomes Study health-related quality of life measures in HIV/AIDS. Qual Life Res 1997;6:531-554.
22. Delate T, Coons SJ. The use of 2 health-related quality-of-life measures in a sample of persons infected with human immunodeficiency virus. Clin Infect Dis 2001;32:E47-E52.
23. Hinderliter AL, Willis PWT, Barst RJ, Rich S, Rubin LJ, Badesch DB, Groves BM, McGoon MD, Tapson VF, Bourge RC, et al. Effects of long-term infusion of prostacyclin (epoprostenol) on echocardiographic measures of right ventricular structure and function in primary pulmonary hypertension. Primary Pulmonary Hypertension Study Group. Circulation 1997;95:1479-1486.
24. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M, Nakanishi N, Miyatake K. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension: comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000;161:487-492.
25. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP, Goldring RM, Groves BM, Kernis JT, et al. Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 1991;115:343-349.
26. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P, Rainisio M, Simonneau G. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002;40:780-788.
27. Raymond RJ, Hinderliter AL, Willis PW, Ralph D, Caldwell EJ, Williams W, Ettinger NA, Hill NS, Summer WR, de Boisblanc B, et al. Echocardiographic predictors of adverse outcomes in primary pulmonary hypertension. J Am Coll Cardiol 2002;9:1214-1219.
28. Tei C, Dujardin KS, Hodge DO, Bailey KR, McGoon MD, Tajik AJ, Seward SB. Doppler echocardiographic index for assessment of global right ventricular function. J Am Soc Echocardiogr 1996;9:838-847.
29. Ghofrani HA, Friese G, Discher T, Olschewski H, Schermuly RT, Weissmann N, Seeger W, Grimminger F, Lohmeyer J. Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension. Eur Respir J 2004;23:321-326.
30. Carlsen J, Kjeldsen K, Gerstoft J. Sildenafil as a successful treatment of otherwise fatal HIV-related pulmonary hypertension. AIDS 2002;16:1568-1569.
31. Zuber JP, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, Nuesch R, Magenta L, Ledergerber B, Jenni R, et al. Pulmonary arterial hypertension related to HIV infection: improved hemodynamics and survival associated with antiretroviral therapy. Clin Infect Dis 2004;38:1178-1185.
32. Burgoyne RW, Saunders DS. Quality of life among urban Canadian HIV/AIDS clinic outpatients. Im J STD AIDS 2001;12:505-512.
33. Dingemanse J, van Giersbergen PLM. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet (In press)